Obesity pills in Eli Lili show promising weight loss in new results

Experimental birth control pills Before Eli Lily It led to the average weight loss of more than 12 percent of body weight in individuals with obesity, according to the results of the initial experiment announced by the drug maker on Thursday. The birth control pills are supposed to be taken daily and will be an alternative to the famous property to combat obesity in the company ZepboundThe injection drug once every week.

It is called Orforglipron, it is part of a growing category of drugs known as GLP-1SWhich includes Novo Nordisk Ozzic and Wugovi. Medicines mimic a natural hormone in the body that helps regulate blood sugar and enhances the feeling of fullness. The injectable GLP-1 drugs showed weight loss from about 15 to 20 percent.

The 18 -month Eli Lilly experience included more than 3000 adults with an average weight of 228 pounds and 37 BMI, which is considered to be considered obese. They were randomly chosen for the participants to receive either 6, 12, or 36 milligrams of the imaginary medicine. Less dose of OrforiPron has resulted in a loss of less than 8 percent of body weight, or about 18 pounds, and the middle dose led to a 9 percent decrease, or 21 pounds.

The highest dose led to a larger weight loss – 12 percent on average, or about 27 pounds, compared to 2 pounds with a placebo. At the highest doses, about 60 percent of the participants lost at least 10 percent of body weight, while 40 percent lost 15 percent or more.

Participants who received OrforiPron started studying at a dose of 1 milligram per day and then increased the dose every four weeks to the final maintenance dose. Everyone has also been described in the experiment, including those in the imaginary medicine group, as a healthy diet and physical activity. There were no food or water restrictions to take birth control pills.

The pill was safe, but like the injected GLP-1 drugs, OrforiPron caused intestinal side effects for many participants. The nausea was the most common, which was suffered by a third of the participants in the highest doses; Constipation has seen about a quarter of patients in that group, as well as diarrhea and vomiting. These side effects led to more than 20 percent of the participants in each group during the study.

Elie Lily says more detailed results will be presented in September in the European Association to study the annual diabetes meeting and published in its journal a review of peers. Novo Nordisk has a GLP-1 diabetes, Rybelsus, but it is not effective to lose weight like injections and has never been approved for weight management.

Orforglipron appears to be promising as a diabetes treatment. in A recent study Posted in New England Medicine, birth control pills reduced blood and weight levels in people with type 2 diabetes. Eli Lily says it plans to provide or forforglipon for organizational review by the end of the year.

Novo Nordisk has a GLP-1 diabetes, Rybelsus, but it is not effective to lose weight like injections and has never been approved for weight management. The challenge in developing the birth control pills was more effective is how to improve biological availability – the amount of medication that enters blood circulation and has an active effect. Other GLP-1 medications consist of larger molecules that cannot be easily absorbed into the digestive system. Instead, most drugs are digested. ELI Lilly may have solved this problem with Orforglipron, the formulation of a small molecule.